1:Screening hysteroscopy is currently not recommended for routine clinical use.
2:Screening hysteroscopy can be considered in patients with recurrent implantation failure.
3:The presently available endometrial receptivity tests are not recommended.
4:Peripheral blood tests for immune parameters and uNK-cell testing are not recommended.
5:KIR and HLA genotyping is currently not recommended for routine clinical use.
6:Immunomodulating treatments, such as Intralipid, IVIG, rh-LIF, PBMCs, and anti-TNF, are not recommended.
7:Artificial oocyte activation is currently not recommended for routine clinical use.
8Artificial oocyte activation is recommended for complete activation failure (0% 2PN), very low fertilization (<30% fertilization), or globozoospermia.
9:Mitochondrial replacement therapy to affect oocyte quality is not recommended.
10:In vitro activation of dormant follicles is not recommended.
11:Clinical IVM and rescue IVM or natural cycle IVF/M are currently not recommended for routine clinical use.
12: Sperm DNA damage testing is currently not recommended for routine clinical use.
13:Artificial sperm activation is currently not recommended for routine clinical use.
14:Artificial sperm activation is recommended for patients with primary or secondary total asthenozoospermia which are not the result of axonemal structure defects.
15:Sperm hyaluronic binding assay is currently not recommended for routine clinical use.
16:Physiological ICSI is currently not recommended for routine clinical use.
17:Magnetic-activated cell sorting is currently not recommended for routine clinical use.
18:Microfluidics can be considered.
19:Intracytoplasmic morphologic sperm injection is currently not recommended for routine clinical use.
20:Growth factor-supplemented embryo culture medium is not recommended.
21:Assisted hatching is not recommended.
22:Pre-implantation genetic testing for aneuploidy is currently not recommended for routine clinical use.
23:Non-invasive PGT is currently not recommended for routine clinical use.
24:Mitochondrial DNA load measurement is currently not recommended for routine clinical use.
25:Time-lapse imaging is not recommended as a tool to improve live birth rates.
26:Intrauterine administration of platelet-rich plasma is not recommended.
27:Intraovarian administration of platelet-rich plasma is not recommended.
28:Duostim is currently not recommended for routine clinical use.
29:Adjuncts (metformin, growth hormone, testosterone, DHEA, aspirin, indomethacin, and sildenafil) before or during ovarian stimulation are not recommended.
30:Intravaginal or intrauterine culture devices are currently not recommended for routine clinical use.
31:Hyaluronic acid addition to transfer media is recommended. Monitoring of the multiple pregnancy rate is still advisable.
32:Endometrial scratching is currently not recommended for routine clinical use.
33:Intrauterine administration of hCG is not recommended.
34:Intrauterine administration of granulocyte colony-stimulating factor is not recommended.
35:Endometrial administration of embryo culture supernatant is not recommended.
36:Endometrial exposure to seminal plasma is not recommended.
37:Stem cell therapy for premature ovarian insufficiency, diminished/poor ovarian reserve or thin endometrium is not recommended.
38:Glucocorticoids are not recommended in ART.
39:Elective freeze-all is currently not recommended for routine clinical use.
40:ICSI is not recommended for non-male factor infertility.
41:Antioxidant therapy is not recommended in ART.
42:Acupuncture, Chinese and herbal medicine and other complementary therapies are not recommended.